S-calprotectin (S100A8/S100A9): A potential marker of inflammation in patients with psoriatic arthritis

Objective. to analyse levels of s100a8/s100a9 (calprotectin) and selected cytokines,in blood,in patients with psoriatic arthritis (psa). methods. sixty-five patients with psa were examined for clinical manifestations and laboratory measurements of s-calprotectin,esr,hs-crp,and selected cytokines. thirty-two patients had mono-/oligoarthritis and 33 had polyarthritis. s-calprotectin,hs-crp,and cytokines were measured using elisa,immunoturbidimetry,and multiplex technology (bio-plex). patients with psa were compared with 31 healthy controls. results. s-calprotectin and hs-crp levels were significantly higher in patients with psa compared with controls (p < 0.001 and p < 0.001,resp.). patients suffering a polyarthritic disease pattern presented with significantly higher levels of s-calprotectin compared with controls and patients with mono-/oligoarthritis (p < 0.001 and p = 0.017,resp.). the levels of s-calprotectin correlated with hs-crp (p < 0.001; r s = 0.441),swollen joint count (p = 0.002,r s = 0.397),and cxcl10 (p = 0.046,r s = 0.678) but not with any of the other cytokines evaluated. in multiple logistic regression analysis,s-calprotectin was the only variable significantly associated with psoriatic arthritis (p = 0.002,or = 1.006,95% ci = 1.002-1.010). conclusion. s-calprotectin and hs-crp levels were significantly higher in patients with psa. a polyarthritic disease pattern showed higher levels of s-calprotectin than mono-/oligoarthritis. s-calprotectin is considered a potential marker of disease activity in patients with psa. © 2014 claes hansson et al.